Last reviewed · How we verify

NCT05889026

The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity

Completed NA Last updated 5 June 2023
What this trial tests

NA trial testing Extracorporeal shock wave therapy in Stroke in 16 participants. Completed in 8 September 2021.

Timeline
6 August 2020
Primary endpoint
8 September 2021
8 September 2021

Quick facts

Lead sponsorKorea University Guro Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment16
Start date6 August 2020
Primary completion8 September 2021
Estimated completion8 September 2021
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Korea University Guro Hospital

Who can join

Adults 19 to 80, any sex, with Stroke or Hemiplegia, Spastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are few studies on whether botulinum toxin treatment and extracorporeal shock wave therapy are more effective than botulinum toxin alone treatment for post-stroke spasticity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effectiveness of Extracorporeal Shock Wave Therapy after Botulinum Toxin Injection for Post-Stroke Upper Extremity Spasticity: A Randomized Controlled Study.
    Lee J, Yang SN. · · 2024 · cited 4× · PMID 38668622 · DOI 10.3390/toxins16040197

Verify or expand the search:

Other trials of Extracorporeal shock wave therapy

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Korea University Guro Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05889026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing